Abstract:Background: Trastuzumab is a first-line targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive gastric cancer. However, the inevitable occurrence of acquired trastuzumab resistance limits the drug benefit, and there is currently no effective reversal measure. Existing researches on the mechanism of trastuzumab resistance mainly focused on tumor cells themselves, while the understanding of the mechanisms of environment-mediated drug resistance is relatively lacking. This study aimed to further explore the mechanisms of trastuzumab resistance to identify strategies to promote survival in these patients. Methods: Trastuzumab-sensitive and trastuzumab-resistant HER2-positive tumor tissues and cells were collected for transcriptome sequencing. Bioinformatics were used to analyze cell subtypes, metabolic pathways, and molecular signaling pathways. Changes in microenvironmental indicators (such as macrophage, angiogenesis, and metabolism) were verified by immunofluorescence (IF) and immunohistochemical (IHC) analyses. Finally, a multi-scale agent-based model (ABM) was constructed. The effects of combination treatment were further validated in nude mice to verify these effects predicted by the ABM. Results: Based on transcriptome sequencing, molecular biology, and in vivo experiments, we found that the level of glutamine metabolism in trastuzumab-resistant HER2-positive cells was increased, and glutaminase 1 (GLS1) was significantly overexpressed. Meanwhile, tumor-derived GLS1 microvesicles drove M2 macrophage polarization. Furthermore, angiogenesis promoted trastuzumab resistance. IHC showed high glutamine metabolism, M2 macrophage polarization, and angiogenesis in trastuzumab-resistant HER2-positive tumor tissues from patients and nude mice. Mechanistically, the cell division cycle 42 (CDC42) promoted GLS1 expression in tumor cells by activating nuclear factor kappa-B (NF-κB) p65 and drove GLS1 microvesicle secretion through IQ motif-containing GTPase-activating protein 1 (IQGAP1). Based on the ABM and in vivo experiments, we confirmed that the combination of anti-glutamine metabolism, anti-angiogenesis, and pro-M1 polarization therapy had the best effect in reversing trastuzumab resistance in HER2-positive gastric cancer. Conclusions: This study revealed that tumor cells secrete GLS1 microvesicles via CDC42 to promote glutamine metabolism, M2 macrophage polarization, and pro-angiogenic function of macrophages, leading to acquired trastuzumab resistance in HER2-positive gastric cancer. A combination of anti-glutamine metabolism, anti-angiogenesis, and pro-M1 polarization therapy may provide a new insight into reversing trastuzumab resistance.

Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab

The Role of Mucin Gene 1 Mediated Anti-Mkn-45 Cell Invasion

Enhancement of ovarian cancer chemotherapy by delivery of multidrug-resistance gene small interfering RNA using tumor targeting Salmonella.

Catecholamine-Induced Β2-Adrenergic Receptor Activation Mediates Desensitization of Gastric Cancer Cells to Trastuzumab by Upregulating MUC4 Expression.

Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance

MUC1 Induces Acquired Chemoresistance by Upregulating ABCB1 in EGFR-dependent Manner

The molecular mechanism of Trastuzumab resistance in Her2 overexpressing breast cancer cells

Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.

[Effects of Smac Gene Overexpression on Chemotherapeutic Sensitivity of Gastric Cancer Cell Line MKN-45].

Interference of Mucin 1 Inhibits Progression of Colon Carcinoma by Repression of Wnt/β-catenin Signaling.

Effect of RNAi-Mediated Survivin and Hypoxia-Inducible Factor 1α Gene Silencing on Proliferation, Invasion, Migration and Apoptosis of Gastric Cancer BGC-823 Cells

Downregulation of Mirorna‐141 Mediates Acquired Resistance to Trastuzumab and is Associated with Poor Outcome in Breast Cancer by Upregulating the Expression of ERBB4

Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer

Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling

Mir-200C Suppresses Stemness and Increases Cellular Sensitivity to Trastuzumab in HER2+breast Cancer

LncRNA-SNHG7 Enhances Chemotherapy Resistance and Cell Viability of Breast Cancer Cells by Regulating miR-186

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

Effect of suppression of Mcl-1 gene expression via siRNA on TRAIL-induced apoptosis of human gastric cancer SGC7901/ADR cells

Tunicamycin Enhances the Antitumor Activity of Trastuzumab on Breast Cancer in Vitro and in Vivo

Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib